Sandoz joins forces with United Nations to combat a leading cause of child mortality worldwide

  • Sandoz makes long-term commitment to support UN initiative on child mortality
  • Commitment to UN Every Newborn Action Plan involves development and supply of recommended WHO formulation for treating childhood pneumonia
  • Pneumonia is the leading cause of death globally among children under five

Holzkirchen, June 30, 2014 – Sandoz today announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation, as part of the United Nations’ new Every Newborn Action Plan.

The …

/by

Sandoz launches Airflusal® Forspiro® in Sweden, further driving patient access to innovative new respiratory inhaler

  • Sweden is fourth European country to launch Sandoz’s award-winning new inhaler for patients with asthma and COPD
  • Sandoz Sweden launches both 50-500 and 50-250 microgram dosage forms, following national marketing authorization earlier this year
  • Airflusal Forspiro offers proven combination of salmeterol and fluticasone propionate in an innovative new device, co-developed with patients

Holzkirchen, June 23, 2014: Sandoz today announced the launch in Sweden of Airflusal® Forspiro®, an innovative new inhaler for patients with asthma and/or …

/by

Sandoz launches three new products in Japan, including authorized generics of valsartan and zoledronic acid

  • Sandoz Japan launches valsartan, the first authorized generic ARB in Japan. Sandoz also launches authorized generic of Zometa® for i.v. infusion 4mg/5mL and generic version of Preminent® Tablets LD

Tokyo, June 20, 2014 Sandoz announces today the launch in Japan of three new products, including valsartan, a generic version of Novartis’ Diovan® Tablets, zoledronic acid, a generic version of Novartis’ Zometa® for i.v. infusion 4mg/5mL and Losarhyd (losartan potassium/hydrochlorothiazide), a generic version of MSD’s Preminent® Tablets LD.

Valsartan and …

/by

GSK application for preliminary injunction withdrawn just before Cologne Court of appeals was to rule in the case

  • GlaxoSmithKline withdraws application for preliminary injunction on German marketing and distribution of Sandoz’s award-winning AirFluSal® Forspiro®
  • GSK application withdrawn shortly before Cologne Court of Appeals was due to rule in the case, restoring German patient access to AirFluSal
  • Sandoz continues to roll out its innovative and cost-effective respiratory inhaler, co-developed with patients, in Europe and beyond

Holzkirchen, June 16, 2014: Pharmaceutical company GlaxoSmithKline has withdrawn its application for a preliminary …

/by

Sandoz France launches generic Nasonex® nasal spray, the first generic nasal corticoid on the French market

  • French launch is latest milestone in roll-out of Sandoz respiratory portfolio – a key pillar of its strategy to bring differentiated generics to patients and payors worldwide
  • Mometasone Sandoz® is first French specialty generic medicine indicated for treatment of a respiratory condition together with an inhaler
  • Allergic rhinitis affects up to 25% of the population of Western Europe annually

Levallois-Perret, June 2, 2014 – Sandoz, the generic pharmaceuticals division of Novartis, today announces the launch in France of Mometasone Sandoz®, …

/by

Sandoz enhances strategic relationship with Upsher-Smith through marketing agreement for potassium chloride products

Princeton, New Jersey, June 3, 2014 – Sandoz today announced an agreement with Upsher-Smith to obtain exclusive US distribution rights for its branded potassium chloride line of products, Klor-Con®, and market them under the Sandoz name, enhancing its strategic relationship.

“This agreement expands and strengthens our current relationship with Upsher-Smith and helps us create a leading potassium chloride business,” said Peter Goldschmidt, President of Sandoz Inc. “With our extensive distribution system, we will be able to improve patient access to these products, …

/by